Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.

MLA

Crusz, Shanthini M., et al. “Heterogeneous Response and Progression Patterns Reveal Phenotypic Heterogeneity of Tyrosine Kinase Inhibitor Response in Metastatic Renal Cell Carcinoma.” BMC Medicine, vol. 14, Nov. 2016, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12916-016-0729-9.

APA

Crusz, S. M., Yen Zhi Tang, Sarker, S.-J., Prevoo, W., Kiyani, I., Beltran, L., Peters, J., Sahdev, A., Bex, A., Powles, T., & Gerlinger, M. (2016). Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Medicine, 14, 1–9. https://doi.org/10.1186/s12916-016-0729-9

Chicago

Crusz, Shanthini M., Yen Zhi Tang, Shah-Jalal Sarker, Warner Prevoo, Irfan Kiyani, Luis Beltran, John Peters, et al. 2016. “Heterogeneous Response and Progression Patterns Reveal Phenotypic Heterogeneity of Tyrosine Kinase Inhibitor Response in Metastatic Renal Cell Carcinoma.” BMC Medicine 14 (November): 1–9. doi:10.1186/s12916-016-0729-9.